drugset / Trial / NCT03424629

Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis

NCT03424629

Phase 1 Unknown 57 enrolled Tianjin Ever Union Biotechnology Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove that UC-MSCs is safe and effective.

Timeline

Start
2018-06-01
Primary completion
2018-09-30
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule Oral
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg
Subject mesenchymal stem cells Cell therapy 3e+06 cells/kg

Indications